Caplin Point Laboratories Ltd
NSE: CAPLIPOINT BSE: 524742
₹2297.10
-41.10 (1.76%)
Fri, 23 Oct 2026, 04:46 am
Market Cap (in Cr)17940.66
PE Ratio26.32
Dividend0.34
Health Technology
Pharmaceuticals: Major
24.5KCaplin Point Laboratories Ltd Company History
1987
- M/s Triwin Pharmaceuticals was started by Mr. P C Partheeban, Mr. T Palanisamy and Mr. S Karunakaran as a partnership firm
1990
- The Company was incorporated as CAPLIN POINT LABORATORIES PRIVATE LIMITED
- The Company was incorporated by the partners of M/s Triwin Pharmaceuticals alongwith Mr. B A Ahmed
1992
- M/s Triwin Pharmaceuticals started the Export of manufactured formulations
1993
- The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED
- The Company adopted a new set of Articles as applicable to public limited companies
- The Company took over M/s Triwin Pharmaceuticals with effect from 1st September
2010
- Caplin Point Laboratories Ltd recommended a final dividend of Re. 1/- per share
2011
- Caplin Point Laboratories Ltd recommended a final Dividend of Re. 1.50 per share
- Mr. Vivek Siddharth was appointed as the Chief Operating Officer of the Company
2012
- Caplin Point Laboratories Ltd recommended a final dividend of Rs. 2/- per share
- Mr. D. P. Mishra was appointed as a Whole Time Director of the Company
2013
- Mr. Mohanraj was appointed as the Vice President - Finance and Company Secretary of the company
2014
- Caplin commenced its additional line of Production in the area of Suppositories
- Caplin Point Lab was listed on Forbes Asia's '200 Best Billion' 2014
2015
- Caplin Point Lab received EU GMP approval for Sterile Injectable Site
- Caplin Point Lab received Brazil's Anvisa approval for Sterile Injectable Site
2016
- US FDA inspection was completed at Caplin Point's Injectable site
2017
- Caplin Point Laboratories received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ketorolac Tromethamine Injection 30mg/mL
- Caplin Point received USFDA nod for Ketorolac Tromethamine Injection
2018
- USFDA completed inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu
2019
- Caplin Point Laboratories partnered with Baxter Corporation for injectable portfolio
- USFDA completed inspection at Caplin Steriles Injectable site
- Caplin Steriles received USFDA nod for hemorrhage prevention drug
- Caplin Point Labs received an EIR from USFDA for injectable facility
2020
- Caplin Point Laboratories partnered with Xellia for injectable products
- Caplin Point Laboratories received final approval from the US drug regulator for its Abbreviated New Drug Application for Phenylephrine Hydrochloride injection
- Caplin Steriles received USFDA approval for Verapamil Hydrochloride Injection USP
2021
- Caplin Point arm inked a strategic partnership with Canada's JAMP Pharma Group
- Caplin Point Laboratories arm received USFDA nod for Neostigmine Methylsulfate Injection
2023
- Caplin Point Laboratories received the Lifetime Achievement Award 2023
- Caplin Point Laboratories received the Forbes Asia Best Under Billion Award 2023
